▲ Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the β-adrenergic receptor antagonist timolol.
▲ Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective than brinzolamide or timolol monotherapy in lowering IOP in a 6-month, randomized, phase III trial in patients with open-angle glaucoma or ocular hypertension (n = 523). The proportion of patients achieving a mean IOP of <18 mmHg was significantly greater in recipients of brinzolamide/timolol than in recipients of brinzolamide or timolol monotherapy.
▲ The IOP-lowering efficacy of brinzolamide/timolol was maintained for up to 12 months, and was no less effective than dorzolamide 2%/timolol 0.5% solution (dorzolamide/timolol) in a randomized, phase III, noninferiority trial (n = 437).
▲ Brinzolamide/timolol was generally well tolerated and was associated with significantly lower ocular discomfort scores than dorzolamide/timolol. Moreover, a significantly greater number of patients expressed a preference for brinzolamide/timolol over dorzolamide/timolol. The main ocular adverse event was blurred vision, and was not considered to be a safety issue.
This is a preview of subscription content, log in to check access
Acknowledgements and Disclosures
This manuscript was reviewed by: G. Manni, Ophthalmology Department, University of Roma, Roma, Italy; F. Ziemssen, University Eye Hospital, Centre of Ophthalmology, Eberhard Karl University, Tuebingen, Germany
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82(11): 844–51PubMedGoogle Scholar
Kass M, Heuer D, Higginbotham E, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays prevents the onset of open-angle glaucoma. Arch Ophthalmol 2002; 120(6): 701–13PubMedCrossRefGoogle Scholar
Geringer C, Imami N. Medical management of glaucoma. Int Ophthamol Clin 2008; 48(4): 115–41CrossRefGoogle Scholar
Fechtner R, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophtahalmol 2004; 15(2): 132–5CrossRefGoogle Scholar
Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003; 20(12): 919–47PubMedCrossRefGoogle Scholar
Iester M. Brinzolamide. Expert Opin. Pharmacother 2008; 9(4): 653–62Google Scholar
DeSantis L. Preclinical overview of brinzolamide. Surv Opthalmol 2000; 44(Suppl. 2): S119–29CrossRefGoogle Scholar
Heel R, Brogden R, Speight T, et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979; 17(1): 38–55PubMedCrossRefGoogle Scholar
Han JA, Frishman WH, Wu Sun S, et al. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 2008; 16(2): 95–108PubMedCrossRefGoogle Scholar
March W, Ochsner K. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 2000; 129(2): 136–43PubMedCrossRefGoogle Scholar
Kaup M, Plange N, Niegel M, et al. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br J Ophthalmol 2004; 88(2): 257–62PubMedCrossRefGoogle Scholar
Izzotti A, Saccà S, Di Marco B, et al. Antioxidant activity of timolol on endothelial cells and its relevance for glaucoma course. Eye 2008; 22(3): 445–53PubMedCrossRefGoogle Scholar
Kiland J, Gabelt B, Kaufman P. Studies on the mechanism of action of timolol and the effects and redirection of aqueous flow on outflow facility. Exp Eye Res 2004; 78(3): 639–51PubMedCrossRefGoogle Scholar
Korte J, Kaila T, Saari K, et al. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240(6): 430–5PubMedCrossRefGoogle Scholar
Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009; 18(4): 293–300PubMedCrossRefGoogle Scholar
Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1 % and timolol 0.5%. Ophthalmology 2008; 115(10): 1728–34PubMedCrossRefGoogle Scholar
Vold SD, Evans RM, Stewart RH, et al. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2008; 24(6): 601–5PubMedCrossRefGoogle Scholar
Mundorf TK, Rauchman SH, Williams RD, et al. A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008; 2(3): 623–8PubMedGoogle Scholar